Science· 2026Q1
The Virtual Biotech: A multi-agent AI framework for therapeutic discovery and development
- 1citations
- Q1SCImago
- 2026year
Short summary
A multi-agent AI framework, the 'Virtual Biotech,' successfully identified drugs targeting cell-type-specific genes as 48% more likely to reach market with 32% fewer adverse events, based on analysis of 55,984 trials.
AI-generated from the title and abstract; the full text is not read.
Abstract
Drug development requires evidence integration across biological scales and modalities, but relevant tools are fragmented. We introduce the Virtual Biotech, an organization of artificial intelligence (AI) agents modeled on a drug-development company, with agentic divisions spanning target discovery, safety assessment, modality selection, and clinical development. We demonstrate its utility at three drug-development decision points. First, over 37,000 agents annotated outcomes from 55,984 trials and found that drugs targeting cell-type-specific genes were 48% more likely to reach market with 32% fewer adverse events. Second, it integrated multimodal evidence to propose a therapeutic strategy in lung cancer. Third, it analyzed a terminated ulcerative colitis trial and inferred potential mechanisms of failure. These results demonstrate that human-guided multi-agent systems can conduct transparent, multiscale analyses to inform therapeutic-development decisions.
The authors' abstract, as published at the source. Science, 2026 · DOI ↗
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Computational Theory and Mathematics
Computational Theory and MathematicsComputer Science